MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds

Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 260% year on year to $389 million. Its GAAP loss of $3.40 per share was 12.4% above analysts’ consensus estimates.

Is now the time to buy MRNA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strategic partnership in the United Kingdom. Management attributed the strong year-over-year growth to international demand for its COVID vaccine products, with CEO Stéphane Bancel noting, “We grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in the U.K.” Despite these gains, the market reacted negatively, largely due to the impact of a significant litigation settlement and ongoing operating losses. The company also emphasized cost discipline, with adjusted cash costs down 26% year-over-year, but acknowledged that the litigation charge weighed heavily on bottom-line results.

Looking ahead, Moderna’s forward guidance reflects optimism around new product approvals and pipeline advancement, especially in respiratory and oncology portfolios. Management is focused on expanding its commercial footprint, highlighting upcoming regulatory milestones such as the anticipated approval of its flu vaccine in the U.S. and progress in its individualized cancer therapy, Intismeran. CFO James Mock reiterated, “We are expecting total revenue to grow up to 10% in 2026,” as the company targets a balanced revenue mix between the U.S. and international markets. However, potential headwinds remain, including uncertainty in COVID vaccination rates and the outcome of ongoing litigation.

Key Insights from Management’s Remarks

Management linked first quarter revenue growth to international shipments and highlighted progress in both respiratory and oncology pipelines, while also addressing the impact of legal settlements on financial performance.

• International contract deliveries: Revenue growth was predominantly attributed to international shipments, especially under the company’s long-term partnership with the U.K. government. This partnership resulted in a substantial contribution to first quarter sales, and management expects further deliveries in the fall as part of the U.K.’s booster campaign.

• Legal settlement impact: The company’s financial results were affected by the previously announced litigation settlement, which added $878 million to cost of sales for the quarter. While the payment is not due until the third quarter, management highlighted that this one-time charge significantly increased the reported net loss.

• Cost discipline initiatives: Management emphasized a 26% reduction in adjusted cash costs year-over-year, achieved through operational efficiencies, reduced unutilized manufacturing capacity, and lower clinical development expenses as large Phase III respiratory studies wound down.

• Product portfolio expansion: Moderna secured approvals for two new products in Europe—its flu plus COVID combination vaccine (now called mCOMBRIAX) and mNEXSPIKE for COVID—marking its fourth approved product and providing a foundation for future growth in the European respiratory vaccine market.

• Oncology and rare disease pipeline advances: The company initiated a new Phase III trial for Intismeran (its individualized cancer therapy) in early-stage lung cancer and continues to progress other late-stage studies in melanoma, renal cell carcinoma, and rare diseases like propionic acidemia. Several pivotal trial readouts are expected later in the year, which could influence future revenue streams.

Drivers of Future Performance

Moderna’s outlook depends on successful commercialization of upcoming products, geographic expansion, and execution on late-stage clinical programs, while managing litigation and declining COVID vaccine demand.

• New product launches and approvals: Management expects future growth to be driven by potential approvals of its flu vaccine (mRNA-1010) in the U.S., and the commercial roll-out of its flu plus COVID combination vaccine in Europe. These launches are positioned to expand the company’s footprint in large markets and diversify revenue beyond COVID products.

• Pipeline readouts and oncology focus: Upcoming pivotal clinical data for Intismeran in melanoma and lung cancer, as well as late-stage trials in rare diseases, are seen as key value drivers. Management believes positive results could open new revenue streams in oncology and rare disease segments, but cautioned that regulatory and clinical uncertainties remain.

• Cost management and litigation risk: Efforts to streamline operations and reduce cash costs remain a focus, but the company faces lingering risks from ongoing litigation, including a possible additional payment of up to $1.3 billion if legal appeals are unsuccessful. Additionally, management highlighted that future COVID vaccine revenues could decline, partially offset by new product uptake and international partnerships.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) regulatory progress and commercial launch timing for the flu and combination vaccines, especially the U.S. FDA’s decision on mRNA-1010, (2) clinical updates from late-stage oncology and rare disease trials, including Intismeran and propionic acidemia, and (3) the resolution of the outstanding litigation, which could impact future cash flows. Execution on international partnerships and the pace of cost reductions will also be important factors.

Moderna currently trades at $45.12, down from $46.18 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.